Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:06 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin
NCT00814372 · Gilead Sciences · PHASE2 · terminated · last registry update 2026-09-18 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “MBX-102 did not meet the target efficacy profile of HbA1c change.” | – | Registry record, Gilead Sciences |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PPARG within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-09-09Results posted on the registry: Inventiva Pharma, Lanifibranor + Placebo (NCT05232071)
- 2026-08-31Results posted on the registry: University of Texas Southwestern Medical Center, Pioglitazone 45 mg (NCT04370093)
- 2026-08-31Results posted on the registry: Emory University, Oral Anti-diabetes Drugs alone + Basal bolus insulin (NCT04416269)
- 2026-08-31Also stopped (terminated): Emory University, Oral Anti-diabetes Drugs alone + Basal bolus insulin (NCT04416269)
- 2026-07-27Results posted on the registry: The University of Texas at Arlington, Pioglitazone (NCT03471117)
- 2026-07-27Also stopped (terminated): The University of Texas at Arlington, Pioglitazone (NCT03471117)
- 2026-07-16Results posted on the registry: Intercept Pharmaceuticals, Bezafibrate 100 mg + Bezafibrate 200 mg (NCT05239468)
- 2026-07-16Results posted on the registry: Intercept Pharmaceuticals, Obeticholic acid + Bezafibrate 200 MG (NCT04594694)
- 2026-07-16Also stopped (terminated): Intercept Pharmaceuticals, Obeticholic acid + Bezafibrate 200 MG (NCT04594694)
- 2026-06-09Phase 3 first posted: Sun Yat-sen University, Group A (triple combination intensive therapy group) + Group B (standard therapy group) (NCT07635953)
- 2026-06-08Results posted on the registry: Intercept Pharmaceuticals, FDC tablet (OCA 5 mg + BZF 400 mg SR) (NCT06488911)
- 2026-06-08Also stopped (terminated): Intercept Pharmaceuticals, FDC tablet (OCA 5 mg + BZF 400 mg SR) (NCT06488911)
- 2026-04-28Results posted on the registry: University of Maryland, Baltimore, Pioglitazone 15mg (NCT05582707)
- 2026-04-28Also stopped (terminated): University of Maryland, Baltimore, Pioglitazone 15mg (NCT05582707)
- 2026-03-19Results posted on the registry: United States Army Research Institute of Environmental Medicine, Pioglitazone 15mg (NCT06164665)
- 2026-02-20Phase 3 first posted: Zydus Therapeutics Inc., Saroglitazar Magnesium 1 mg + Placebo (NCT07424677)
- 2025-12-18Results posted on the registry: Zydus Therapeutics Inc., Saroglitazar Magnesium 4 mg Tablet + Placebo (NCT03617263)
- 2025-12-18Also stopped (terminated): Zydus Therapeutics Inc., Saroglitazar Magnesium 4 mg Tablet + Placebo (NCT03617263)
- 2025-10-14Phase 3 first posted: Zydus Therapeutics Inc., Saroglitazar magnesium 1 mg + Placebo (NCT07216235)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision